Multiple Sclerosis (MS) Drug Market

RECENT NEWS
SeekingAlpha  11 hrs ago  Comment 
ByRichard Richter: Pathogenic infections are understandable. A foreign organism invades your body and you get sick. The immune system eventually takes care of it, sometimes with the help of other drugs. Autoimmune disorders, on the other hand, are...
Reuters  Apr 7  Comment 
Specialty pharmaceuticals company Mallinckrodt Plc will buy drugmaker Questcor Pharmaceuticals Inc for about $5.6 billion to gain access to its multiple sclerosis drug, Acthar Gel, which...
FierceBiotech  Apr 7  Comment 
Sanofi is walking away from any plans to appeal the FDA's emphatic rejection of the multiple sclerosis drug Lemtrada, at least for now. But rather than launching the added trial that the FDA demanded ahead of any possible approval, the company...
MedPage Today  Mar 20  Comment 
(MedPage Today) -- Two clinical trials are now underway that offer the first tests of an intriguing but still not widely accepted theory of multiple sclerosis -- that its trigger lies within a part of the human genome that medical research has...
SeekingAlpha  Mar 20  Comment 
By Peter Geschek: Multiple sclerosis In 2013 the size of the global MS (multiple sclerosis) market was about $15 billion and the market is growing at a rate of 11 percent annually. Biogen Idec' (BIIB) share of that market was about the third...
guardian.co.uk  Mar 19  Comment 
MS decline may be slowed by use of widely available cholesterol-reducing drug, researchers find A cholesterol-lowering statin taken by large numbers of people in the UK could also help people suffering from advanced multiple sclerosis, according...
FierceBiotech  Mar 18  Comment 
The FDA said it needs three more months to consider Biogen Idec's Plegridy, an injectable multiple sclerosis treatment, delaying an expected midyear launch for the company's latest entrant in its blockbuster MS franchise.
SeekingAlpha  Mar 10  Comment 
By Long Term Bio: (Editor’s Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.) One biotech name that investors...
FiercePharma  Mar 6  Comment 
Merck KGaA's multiple sclerosis treatment Rebif is holding its own. Considering that the German drugmaker's flagship product faces some formidable new competitors--including Biogen Idec's brand-new powerhouse, Tecfidera--that's not too shabby.




 
TOP CONTRIBUTORS

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki